Patents Examined by Elizabeth C. Kemmerer
  • Patent number: 11897948
    Abstract: The invention provides methods and compositions for treating a subject having a renal-related disorder, such as chronic kidney disease (CKD), end stage renal failure, diabetes, insulin resistance, kidney hypertrophy, kidney hypotrophy, polycystic kidney disease, proteinuria, hyperglycemia, hyperuricemia, gout, kidney stones, hypertension or hypertensive nephropathy, dyslipidemia, anemia and/or reduced erythropoietin production, iron deficiency or hyperfiltration. The methods and compositions use or contain a composition that reduces or inhibits GDF15 activity.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: February 13, 2024
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Jeno Gyuris, Lorena Lerner
  • Patent number: 11890353
    Abstract: The present invention provides methods of making an in vivo animal model for detecting anti-poly(ethylene glycol) (PEG) antibodies. The methods of the disclosure comprises administering subcutaneously to an animal model a composition comprising antibodies against poly(ethylene glycol) chains with a molecular weight of at least 550 Da to maintain an anti-PEG antibody level within the animal model. The in vivo animal model can be used for testing and screening drugs and other compositions for adverse reactions, bioavailability, and immunogenicity prior to administration to a human subject.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: February 6, 2024
    Assignee: Northwestern University
    Inventors: Evan A. Scott, Guillermo A. Ameer, Jacqueline A. Burke, Helena Freire Haddad
  • Patent number: 11891438
    Abstract: The present invention provides a method of promoting local bone growth by administering a therapeutic amount of a Sost antagonist to a mammalian patient in need thereof. Preferably, the Sost antagonist is an antibody or FAB fragment selectively recognizing any one of SEQ ID NOS: 1-23. The Sost antagonist may be coadministered together or sequentially with a matrix conducive to anchoring new bone growth. Orthopedic and Periodontal devices comprising an implantable portion adapted to be permanently implanted within a mammalian body and bearing an external coating of a Sost antagonist are also disclosed, as it a method of increasing bone density by administering to a mammalian patient a therapeutic amount of a Sost antagonist together with an antiresorptive drug.
    Type: Grant
    Filed: June 21, 2023
    Date of Patent: February 6, 2024
    Assignee: OSSIFI-MAB LLC
    Inventor: Debra L. Ellies
  • Patent number: 11890354
    Abstract: The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: February 6, 2024
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu, James William West, Jason Gary Sagert, Olga Vasiljeva, Elizabeth-Edna Mary Menendez
  • Patent number: 11891428
    Abstract: The present application provides methods and processes for making and using a fibronectin composition, as well as methods for treating ocular conditions and/or disorders with the cellular fibronectin composition described herein.
    Type: Grant
    Filed: July 8, 2022
    Date of Patent: February 6, 2024
    Assignee: COMBANGIO, INC.
    Inventors: Spencer Alford, Audrey Smith
  • Patent number: 11891447
    Abstract: Methods for treating cancer and/or reducing sternness of cancer stem cells in a subject using a CD14 antagonist, which may be an anti-CD14 antibody.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: February 6, 2024
    Assignee: NATIONAL TAIWAN UNIVERSITY
    Inventor: Huei-Wen Chen
  • Patent number: 11891423
    Abstract: Provided by the present invention are a fusion protein binding to a CD47 protein and an application thereof, wherein the fusion protein is capable of binding to a CD47 protein by using a KD value of 1×10?8M or lower. The fusion protein may specifically block the interaction between a CD47 protein and SIRP? without causing a blood coagulation reaction, and may further inhibit the growth and/or proliferation of tumors or tumor cells.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: February 6, 2024
    Assignees: HANGZHOU SUMGEN BIOTECH CO., LTD., SUMGEN MAB (BEIJING) BIOTECH CO., LTD.
    Inventors: Ming Lv, Xiaoran Ding, Shiwei Miao, Bin Tan, Xuegong Wang
  • Patent number: 11891436
    Abstract: The present invention relates to novel monoclonal anti-human-GDF-15 antibodies, pharmaceutical compositions, kits, methods and uses and the cell lines capable of producing the monoclonal antibodies described herein. The present invention further relates to novel antibodies to human GDF-15 capable of inhibiting cancer growth.
    Type: Grant
    Filed: August 11, 2020
    Date of Patent: February 6, 2024
    Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG
    Inventors: Jörg Wischhusen, Markus Junker, Thomas Müller, Stefan Saremba
  • Patent number: 11884719
    Abstract: The present invention provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human IL-36 cytokines, IL-36?, IL-36?, and/or IL-36?, and block the IL-36 stimulated signaling pathways. Compositions comprising such binding proteins and methods of making and using such binding proteins are also provided.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: January 30, 2024
    Assignee: 23andMe, Inc.
    Inventors: Chingwei Vivian Lee, Germaine Fuh-Kelly, Louise Scharf, Tina Thai, Ashka Bharat Patel, Shashank Bharill, Erik Edward Karrer
  • Patent number: 11857599
    Abstract: In certain aspects, the disclosure provides compositions and methods for treating spinal muscular atrophy. For example, in some embodiments, the disclosure provides ALK4:ActRIIB antagonists that may be used to treat spinal muscular atrophy, particularly treating one or more complications of spinal muscular atrophy including, for example, increasing muscle mass muscle strength, and bone mineral density.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: January 2, 2024
    Assignee: Acceleron Pharma Inc.
    Inventors: Ravindra Kumar, Rajasekhar Naga Venkata Sai Suragani, Jia Li
  • Patent number: 11860169
    Abstract: The present invention provides a method of treating a subject in need thereof comprising classifying the subject into functional group FG1, FG2 or FG3, wherein i) when the subject is classified into the FG1 functional group, (A) the level of OPN or the activity of OPN in said subject is increased; (B) the subject is not treated with a brace; or (C) a combination of (A) and (B); and ii) when the subject is classified into the FG2 or FG3 functional group, (A) the level of OPN or the activity of OPN in said subject is decreased; (B) the subject is treated with a brace; or (C) a combination of (A) and (B).
    Type: Grant
    Filed: September 8, 2020
    Date of Patent: January 2, 2024
    Assignee: CHU SAINTE-JUSTINE
    Inventors: Alain Moreau, Marie-Yvonne Akoume Ndong
  • Patent number: 11857576
    Abstract: The present disclosure provides compositions and methods for repairing cartilage defects.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: January 2, 2024
    Assignee: Vericel Corporation
    Inventors: Ross A. Tubo, Xing Zhao
  • Patent number: 11851490
    Abstract: Disclosed are methods and compositions for treating, inhibiting, and/or preventing heterotopic ossification in a subject in need thereof. Particularly disclosed are methods for treating, inhibiting, and/or preventing heterotopic ossification in a subject in need thereof by administering to the subject a therapeutic agent such as an immune checkpoint inhibitor and/or Fetuin-A or a variant thereof. Also disclosed are pharmaceutical compositions and pharmaceutical kits comprising an immune checkpoint inhibitor and/or Fetuin-A or a variant thereof for treating, inhibiting, and/or preventing heterotopic ossification in a subject in need thereof.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: December 26, 2023
    Assignee: Northwestern University
    Inventors: Lixin Kan, John A. Kessler
  • Patent number: 11827698
    Abstract: Provided herein are proteins, antibodies, assays and methods useful for modulating growth factor levels and/or activities. In some embodiments, such growth factors are members of the TGF-? superfamily of proteins.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: November 28, 2023
    Assignee: Scholar Rock, Inc.
    Inventors: Thomas Schurpf, Nagesh K. Mahanthappa, Michelle Straub
  • Patent number: 11826401
    Abstract: The present inventors have found that HMGB1 fragment peptides having a particular amino acid sequence exhibit the effects of improvement of cardiac function, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of dilated cardiomyopathy, that the particular HMGB1 fragment peptides also exhibit the effects of improvement of cardiac function, inhibition of cardiomegaly, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of ischemic cardiomyopathy caused by old myocardial infarction, and that the particular HMGB1 fragment peptides exhibit the effects of inhibition of cardiomyocyte hypertrophy and inhibition of myocardial fibrosis in an animal model of hypertensive cardiomyopathy.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: November 28, 2023
    Assignees: STEMRIM INC., OSAKA UNIVERSITY
    Inventors: Katsuto Tamai, Yoshiki Sawa, Shigeru Miyagawa, Takashi Kido, Takasumi Goto, Takehiko Yamazaki
  • Patent number: 11813311
    Abstract: Methods of treating and preventing metabolic disease through inhibiting interleukin 11 (IL-11)-mediated signalling are disclosed, as well as agents for use in such methods.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: November 14, 2023
    Assignees: Singapore Health Services PTE LTD., National University of Singapore
    Inventors: Stuart Alexander Cook, Sebastian Schaefer, Brijesh Kumar Singh, Anissa Widjaja
  • Patent number: 11813308
    Abstract: Provided herein are methods of treating diseases associated with vascular calcification and/or cardiovascular disease in a subject by using the level of a biomarker, in particular, snail homolog 1 (Snai1), phosphosmad2, phosphosmad3, urinary protein, dickkopf homolog 1 (Dkk1), collagen type 1 alpha 1 (Col1a1), activin (e.g., free activin), runt-related transcription factor 2 (Runx2), alkaline phosphatase (Alp), bone-specific alkaline phosphatase (BSAP), C-terminal type 1 collagen telopeptide (CTX), osterix, Klotho, alpha-smooth muscle actin (alpha-SMA), myocardin (MYOCD), activin receptor type 2A (ActRIIA), axis inhibition protein 2 (Axin2), and/or smooth muscle protein 22-alpha (Sm22-alpha), as an indicator(s) of responsiveness of the subject to the treatment, efficacy of the treatment, or appropriate dosage for the treatment with an activin type II receptor signaling inhibitor.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: November 14, 2023
    Assignees: Celgene Corporation, Washington University
    Inventors: Keith Hruska, Yifu Fang, William Smith, Nianhang Chen
  • Patent number: 11807681
    Abstract: The present invention provides a method of promoting local bone growth by administering a therapeutic amount of a Sost antagonist to a mammalian patient in need thereof. Preferably, the Sost antagonist is an antibody or FAB fragment selectively recognizing any one of SEQ ID NOS: 1-23. The Sost antagonist may be coadministered together or sequentially with a matrix conducive to anchoring new bone growth. Orthopedic and Periodontal devices comprising an implantable portion adapted to be permanently implanted within a mammalian body and bearing an external coating of a Sost antagonist are also disclosed, as it a method of increasing bone density by administering to a mammalian patient a therapeutic amount of a Sost antagonist together with an antiresorptive drug.
    Type: Grant
    Filed: March 20, 2023
    Date of Patent: November 7, 2023
    Assignee: OSSIFI-MAB LLC
    Inventor: Debra L Ellies
  • Patent number: 11773149
    Abstract: This invention provides an NBP158 recombinant protein, a recombinant or synthetic NBP158 mutant protein, a pharmaceutical compositions comprising the NBP158 recombinant protein, and a method for treating metabolic disorders and conditions using such a pharmaceutical composition.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: October 3, 2023
    Inventor: Wentao Zhang
  • Patent number: 11773173
    Abstract: In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: October 3, 2023
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Akihisa Kaneko, Yuki Iwayanagi, Hidetomo Kitamura, Yoshinobu Higuchi, Hiroaki Matsushita, Ryosuke Mihara, Yumi Yamamoto, Tomohisa Saito, Keiko Hirokawa